Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will be attending and presenting at SLEEP 2022. The event is the annual meeting of the Associated Professional Sleep Societies (“APSS”), which is a joint venture of the American Academy of Sleep Medicine (“AASM”) and Sleep Research Society (“SRS”); thousands of sleep experts attend the event every year. The meeting is scheduled for June 4–8, 2022, and will be held in Charlotte, North Carolina. In addition to attending the event, Vivos Therapeutics’ leaders will offer two presentations. Vivos medical advisory board member Dr. Seth Heckman will be part of a poster session slated for June 6 at 5:15 p.m. ET. Heckman’s presentation, titled “Non-Surgical Maxillary Expansion Using a Novel Oral Appliance System,” will provide an overview of a retrospective study recently conducted involving Vivos patients. Dr. Clete Kushida, cochair of the Vivos medical advisory board, will chair a symposium held on June 8 at 3:15 p.m. ET. During that symposium, Dr. J. Steven Alexander, a molecular physiologist working on cellular mechanisms underlying maxillary modeling in adults with OSA, will talk about the Vivos Method. SLEEP 2022 is a premier event designed to provide evidence-based education and information to advance sleep medicine’s science and clinical practice as well as disseminate sleep and circadian research and promote basic science translation into clinical practice and more.
To view the full press release, visit https://ibn.fm/ULz79
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from dentofacial abnormalities or mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution and has proven effective in the treatment of an estimated 27,000 patients worldwide by more than 1,500 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivosScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
